Equities researchers at StockNews.com assumed coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV – Get Free Report) in a note issued to investors on Thursday. The brokerage set a “hold” rating on the biotechnology company’s stock.
Nabriva Therapeutics Price Performance
NASDAQ NBRV opened at $0.00 on Thursday. The firm has a market capitalization of $6,403.00, a PE ratio of 0.00 and a beta of 1.53. Nabriva Therapeutics has a 52 week low of $1.22 and a 52 week high of $8.45. The company has a quick ratio of 0.52, a current ratio of 0.85 and a debt-to-equity ratio of 0.12.
Nabriva Therapeutics Company Profile
Featured Articles
- Five stocks we like better than Nabriva Therapeutics
- Trading Stocks: RSI and Why it’s Useful
- 3 Micro-Caps Set for Major Moves: Balancing Risk and Opportunity
- How to Invest in the Best Canadian Stocks
- Autodesk Named a “Top Pick” by Morgan Stanley—Is It Time to Buy?
- What is a Stock Market Index and How Do You Use Them?
- 4 Quirky ETFs With Big Potential for Impressive Gains
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.